Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug123 | ARBOX Wiki | 0.71 |
| drug4009 | Thrombin Generation Assay (TGA) Wiki | 0.71 |
| drug4011 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004211 | Disseminated Intravascular Coagulation NIH | 0.35 |
| D020141 | Hemostatic Disorders NIH | 0.18 |
| D001778 | Blood Coagulation Disorders NIH | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005521 | Disseminated intravascular coagulation HPO | 0.35 |
| HP:0001928 | Abnormality of coagulation HPO | 0.18 |
Navigate: Correlations HPO
There are 2 clinical trials
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.
Description: defined as the time from first dose of polyphenol extract to hospital discharge
Measure: Time to hospital discharge Time: Throughout the Study (Day 0 to Day 28)Description: proportion
Measure: 28-day all-cause mortality Time: Throughout the Study (Day 0 to Day 28)Description: proportion
Measure: invasive ventilation on day 28 Time: Throughout the Study (Day 0 to Day 28)Description: mean difference
Measure: Difference in Pro and antiinflammatory citoquine levels Time: day 1-14Description: proportion
Measure: Negativization of COVID-PCR at day 14 Time: day 14The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measured from serum; iii) reduce clinical and emotional symptoms through daily clinical evaluation; iv) improve sleep; v) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients.
Description: Deterioration in clinical status from mild/moderate to severe/critical over time during the study period
Measure: Prevention of severe/critical stage of Covid19 Time: Up to 28 daysDescription: Clinical CoVid19 symptoms Clinical improvement
Measure: Time to CoVid19 symptoms relief and number of participants with negative Clinical CoVid19 symptoms as assessed by CTCAE v5.0 Time: Up to 28 daysDescription: Immune reaction
Measure: Change in proinflammatory cytokine concentration Time: Up to 28 daysDescription: A qualitative CT analysis of parenchymal lung damage induced by COVID-19
Measure: Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT Time: 14 daysDescription: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Up to 28 daysDescription: Time to clinical improvement
Measure: Time to clinical improvement with CTCAE v5.0 CoVid19 symptoms to 0 Time: Up to 28 daysDescription: CoVid severity worsening
Measure: Number of participants that need hospitalisation Time: Up to 28 daysDescription: Mortality
Measure: 28-day mortality Time: Up to 28 daysDescription: Time to negative saliva
Measure: Time to positive-to-negative saliva 2019-n-CoV RT-PCR conversion Time: Up to 28 daysDescription: Mean reduction in viral load (reduction of ≥1 log10) over time during the study period
Measure: Reduction in viral load Time: Up to 28 daysDescription: Brief measure for assessing generalized anxiety disorder (The GAD-7) and depression (PHQ-9)
Measure: Brief measure for assessing generalized anxiety disorder and depression Time: Through study completion, over time during the study period (day 0-28)]Description: Scores of the brief peanut butter olfactory test (Univ Florida)
Measure: Increment of odor detection sensitivity Time: Through study completion, over time during the study period (day 0-28)]Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports